An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Public ClinicalTrials.gov record NCT05011058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Study identification
- NCT ID
- NCT05011058
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Viracta Therapeutics, Inc.
- Industry
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- Nanatinostat in combination with valganciclovir Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2021
- Primary completion
- Dec 25, 2024
- Completion
- Jan 30, 2025
- Last update posted
- Jul 27, 2025
2021 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35233 | — |
| City of Hope | Duarte | California | 91010 | — |
| David Geffen School of Medicine - UCLA | Los Angeles | California | 90095 | — |
| University of California Irvine | Orange | California | 92868 | — |
| Scripps MD Anderson Cancer Center | San Diego | California | 92103 | — |
| UCSF Hematology and Blood and Marrow Transplant | San Francisco | California | 94143 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| John Theurer Cancer Center: Hackensack Univeristy | Hackensack | New Jersey | 07601 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| Ohio State University: Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Sidney Kimmel Cancer Center - Jefferson Health | Philadelphia | Pennsylvania | 19107 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Harold C. Simmons Comprehensive Cancer Center | Dallas | Texas | 75235 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Utah, Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05011058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 27, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05011058 live on ClinicalTrials.gov.